Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients

被引:1
作者
Amit Bahl
Steven Johnson
Nai-Wei Chen
机构
[1] Beaumont Hospital,Department of Emergency Medicine
[2] Beaumont Health Research Institute,undefined
来源
Internal and Emergency Medicine | 2021年 / 16卷
关键词
Corticosteroids; Timing; COVID-19; Coronavirus; Treatment; Mortality;
D O I
暂无
中图分类号
学科分类号
摘要
The optimal timing of initiating corticosteroid treatment in hospitalized patients is unknown. We aimed to assess the relationship between timing of initial corticosteroid treatment and in-hospital mortality in COVID-19 patients. In this observational study through medical record analysis, we quantified the mortality benefit of corticosteroids in two equally matched groups of hospitalized COVID-19 patients. We subsequently evaluated the timing of initiating corticosteroids and its effect on mortality in all patients receiving corticosteroids. Demographic, clinical, and laboratory variables were collected and employed for multivariable regression analyses. 1461 hospitalized patients with confirmed COVID-19 were analyzed. Of these, 760 were also matched into two equal groups based on having received corticosteroid therapy. Patients receiving corticosteroids had a lower risk of death than those who did not (HR 0.67, 95% CI 0.67–0.90; p = 0.01). Timing of corticosteroids was assessed for all 615 patients receiving corticosteroids during admission. Patients receiving first dose of corticosteroids > 72 h into hospitalization had a lower risk of death compared to patients with first dose at earlier time intervals (HR 0.56, 95% CI 0.38–0.82; p = 0.003). There was a mortality benefit in patients with > 7 days of symptom onset to initiation of corticosteroids (HR 0.56, 95% CI 0.33–0.95; p = 0.03). In patients receiving oxygen therapy, corticosteroids reduced risk of death in mechanically ventilated patients (HR 0.38, 95% CI 0.24–0.60; p < 0.001) but not in patients on high-flow or other oxygen therapy (HR 0.46, 95% CI 0.20–1.07; p = 0.07) and (HR 0.84, 95% CI 0.35–2.00; p = 0.69), respectively. Timing of corticosteroids initiation was related to in-hospital mortality for COVID-19 patients. Time from symptom onset > 7 days should trigger initiation of corticosteroids. In the absence of invasive mechanical ventilation, corticosteroids should be initiated if the patient remains hospitalized at 72 h. Hypoxia requiring supplemental oxygen therapy should not be a trigger for initiation of corticosteroids unless the timing is appropriate.
引用
收藏
页码:1593 / 1603
页数:10
相关论文
共 27 条
[1]  
Beigel JH(2020)Remdesivir for the Treatment of Covid-19 — Final Report N Engl J Med 383 1813-1826
[2]  
Tomashek KM(2020)Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State JAMA 323 2493-309
[3]  
Dodd LE(2004)Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients J Clin Virol 31 304-2120
[4]  
Rosenberg ES(2020)Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19 Clin Infect Dis 71 2114-1499
[5]  
Dufort EM(2020)Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort Intern Emerg Med 15 1485-undefined
[6]  
Udo T(2019)The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis Crit Care 23 99-undefined
[7]  
Lee N(2020)Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 JAMA 324 1330-undefined
[8]  
Allen Chan KC(2020)Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 JAMA 324 1307-undefined
[9]  
Hui DS(2020)Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 JAMA 324 1317-undefined
[10]  
Fadel R(undefined)undefined undefined undefined undefined-undefined